MicroRNA-32 Suppression: its Effects on Prostate Cancer Cells' Capability to Proliferate and Migrate.

IF 1.7 Q3 PHARMACOLOGY & PHARMACY

Drug Research Pub Date : 2023-03-01 DOI:10.1055/a-1977-8848

Farah A Al-Marzook, Duha Maithem Hassan, Maha Waleed Alghazal, Rana Abd Alameer Kadheem, Abduladheem Turki Jalil, Marwan Mahmood Saleh

{"title":"MicroRNA-32 Suppression: its Effects on Prostate Cancer Cells' Capability to Proliferate and Migrate.","authors":"Farah A Al-Marzook, Duha Maithem Hassan, Maha Waleed Alghazal, Rana Abd Alameer Kadheem, Abduladheem Turki Jalil, Marwan Mahmood Saleh","doi":"10.1055/a-1977-8848","DOIUrl":null,"url":null,"abstract":"Introduction: This paper sought to scrutinize the role of microRNA-32 (miR-32) on the growth and migration as well as on the expression of metastatic genes in PC3 cells of prostate cancer in vitro.Methods: Subsequent transfection of cells with miR-32 mimics, miR-32 inhibitor, negative control (NC), cell proliferation using MTT, and apoptosis by ELISA were performed. Furthermore, qRT-PCR was directed to measure the expression levels of matrix metalloproteinase 2 (MMP2) and vascular endothelial growth factors (VEGF) as metastatic and angiogenesis genes in the progression of PC3.Results: miR-32 was overexpressed in PC3 cells compared to normal cells (P<0.001). Down-regulation of miR-32 obstructs in vitro proliferation and migration while intensifying the apoptosis rate in PC3 cells. Also, we found that miR-32 negatively modulates the expression of VEGF and MMP2 in PC3 cells.Conclusion: These results indicate that the suppression of miR-32 might offer an auxiliary treatment procedure for addressing the invasion, progression, and metastasis in PCa patients by improving cell apoptosis.","PeriodicalId":11451,"journal":{"name":"Drug Research","volume":"73 3","pages":"170-174"},"PeriodicalIF":1.7000,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"4","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Drug Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1055/a-1977-8848","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 4

Abstract

Introduction: This paper sought to scrutinize the role of microRNA-32 (miR-32) on the growth and migration as well as on the expression of metastatic genes in PC3 cells of prostate cancer in vitro.

Methods: Subsequent transfection of cells with miR-32 mimics, miR-32 inhibitor, negative control (NC), cell proliferation using MTT, and apoptosis by ELISA were performed. Furthermore, qRT-PCR was directed to measure the expression levels of matrix metalloproteinase 2 (MMP2) and vascular endothelial growth factors (VEGF) as metastatic and angiogenesis genes in the progression of PC3.

Results: miR-32 was overexpressed in PC3 cells compared to normal cells (P<0.001). Down-regulation of miR-32 obstructs in vitro proliferation and migration while intensifying the apoptosis rate in PC3 cells. Also, we found that miR-32 negatively modulates the expression of VEGF and MMP2 in PC3 cells.

Conclusion: These results indicate that the suppression of miR-32 might offer an auxiliary treatment procedure for addressing the invasion, progression, and metastasis in PCa patients by improving cell apoptosis.

查看原文本刊更多论文

抑制MicroRNA-32对前列腺癌细胞增殖和迁移能力的影响

本文旨在探讨microRNA-32 (miR-32)在前列腺癌PC3细胞的生长、迁移和转移基因表达中的作用。方法:随后用miR-32模拟物、miR-32抑制剂、阴性对照(NC)转染细胞，MTT法进行细胞增殖，ELISA法进行细胞凋亡。此外，qRT-PCR检测基质金属蛋白酶2 (MMP2)和血管内皮生长因子(VEGF)作为转移性和血管生成基因在PC3进展中的表达水平。结果:与正常细胞相比，miR-32在PC3细胞中过表达(结论:这些结果表明，抑制miR-32可能通过改善细胞凋亡，为解决PCa患者的侵袭、进展和转移提供了一种辅助治疗方法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Drug Research PHARMACOLOGY & PHARMACY-

CiteScore

3.50

自引率

0.00%

发文量

期刊介绍： Drug Research (formerly Arzneimittelforschung) is an international peer-reviewed journal with expedited processing times presenting the very latest research results related to novel and established drug molecules and the evaluation of new drug development. A key focus of the publication is translational medicine and the application of biological discoveries in the development of drugs for use in the clinical environment. Articles and experimental data from across the field of drug research address not only the issue of drug discovery, but also the mathematical and statistical methods for evaluating results from industrial investigations and clinical trials. Publishing twelve times a year, Drug Research includes original research articles as well as reviews, commentaries and short communications in the following areas: analytics applied to clinical trials chemistry and biochemistry clinical and experimental pharmacology drug interactions efficacy testing pharmacodynamics pharmacokinetics teratology toxicology.